Five Prime Therapeutics, Inc. $115 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “FPRX.”

Goldman Sachs & Co. LLC, J.P. Morgan, Leerink Partners, Wells Fargo Securities acted as Joint-bookrunners on the offering.

Five Prime Therapeutics, Inc. is a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics. Five Prime’s discovery platform positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture), counsel Jeffrey Gould and associates Josephine Chen and Lucas Tejwani. The tax team included partner Rachel D. Kleinberg and associate Caroline E. Dayton. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Jeffrey Gould – Davis Polk & Wardwell; Josephine Chen – Davis Polk & Wardwell; Lucas Tejwani – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Caroline Dayton – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman, Sachs & Co.; JP Morgan; Leerink Partners; Wells Fargo Securities;


Author: Ambrogio Visconti